Topic: How To Invest

Power Growth Investor Hotline – Friday June 20, 2025

Article Excerpt

ELI LILLY AND COMPANY, $762.73, is a buy. The drugmaker (symbol LLY on New York) discovers, develops, manufactures and markets human pharmaceutical products. Lilly has now agreed to acquire Verve Therapeutics. The purchase price is $1 billion upfront. It could pay as much as an additional $300 million based on Verve’s lead treatment achieving certain clinical milestones. Verve is a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease such as treating bad cholesterol. Its lead program, Verve-102, is a potential first-in-class in vivo gene-editing medicine targeting PCSK9, a gene linked to cholesterol levels and cardiovascular health. The treatment is being evaluated in a Phase 1B clinical trial study and has been granted fast-track designation by the Food and Drug Administration. Notably, by editing a person’s genetic instructions for a cholesterol-boosting molecule, a single infusion of Verve’s treatment could cut cholesterol for a lifetime. In a Phase 1 trial reported in April, participants’ levels of the harmful LDL-C cholesterol fell nearly 60% with no side…